LONDON BROKER RATINGS: Haleon hit with price target cuts by 7 brokers
30th Oct 2026 09:46
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Monday: Read More
(Alliance News) - Stock prices in London opened higher on Thursday, with gains for oil major Shell helping the FTSE 100 advance, but earnings for banking firm Lloyds failed to inspire. Read More
(Alliance News) - Lloyds Banking Group reports a sharp rise in third-quarter profit, while Shell more than doubles its earnings and announces a USD5 billion share buyback. Premier Inn owner Whitbread expects to benefit from UK budget measures limiting business rates increases for hospitality businesses. Read More
(Alliance News) - Stocks in London ended mixed on Wednesday as investors assessed Chancellor John Healey's first budget and looked ahead to an expected US interest rate hold. Read More
(Alliance News) - Stock prices in London were mixed at midday on Wednesday, with the FTSE 100 edging lower ahead of Chancellor John Healey's first budget, though banking stocks rallied on a report that a planned tax increase on the sector would be less severe than feared. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday. Read More
(Alliance News) - GSK PLC on Wednesday reported better-than-expected earnings, largely driven by improved margins and lower costs, although sales growth was limited by a weaker-than-hoped performance in its Vaccines division. Read More
(Alliance News) - Stock prices in London opened lower on Wednesday, as investors braced for Chancellor John Healey's first budget and the US Federal Reserve's interest rate decision, while losses for GSK and Unilever weighed on the FTSE 100. Read More
(Alliance News) - GSK reports a fall in third-quarter profit despite higher revenue, while Unilever upgrades its full-year volume growth outlook. Aston Martin narrows its third-quarter loss as revenue jumps, driven by deliveries of its Valhalla supercar. Read More
(Alliance News) - GSK PLC has announced positive results from tests of its drug candidates for rectal and ovarian cancer. Read More
(Alliance News) - Computacenter raises its full-year profit outlook after strong third-quarter trading, while Plus500 forecast annual revenue and earnings ahead of market expectations. GSK has reported positive clinical trial results for two cancer treatments. Read More
(Alliance News) - GSK PLC on Wednesday noted five-year data for ViiV Healthcare's HIV treatment Cabenuva, which the lead study author found "highly encouraging". Read More
(Alliance News) - GSK PLC on Wednesday announced US regulatory approval for its chronic hepatitis B treatment Hibsago, while Hutchmed China Ltd confirmed the completion of a separate licensing agreement with GSK worth up to USD1.30 billion. Read More
(Alliance News) - Fresnillo says it has maintained its annual production forecast, GSK has landed a US drug approval and Quilter reports its net inflows for the year have already topped 2025's level. Meanwhile, drilling at a North Sea gas field co-owned by Shell has been approved. Read More
(Alliance News) - GSK PLC on Monday announced an approval for Jemperli in the US for a form of locally advanced rectal cancer. Read More
(Alliance News) - GSK PLC on Monday set out its first batch of global data for the risvutatug rezetecan drug. Read More
(Alliance News) - LondonMetric reports growth in rental income over its first half, GSK posts promising results from a drug trial while Volex expects annual profit at the upper end of market forecasts. Meanwhile, Abenojar Tungsten, set to list later this month, could be worth more than GBP600 million. Read More
(Alliance News) - The FTSE 100 ended higher on Wednesday, despite strong US inflation data, as the Bank of England's chief economist played down fears of multiple interest rate rises in the UK. Read More